Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: trastuzumab|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: lapatinib ditosylate|DRUG: paclitaxel|OTHER: laboratory biomarker analysis
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: National Cancer Institute (NCI)|Dana-Farber Cancer Institute|GlaxoSmithKline